國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Incentives for research, development...

Garcia-Fontes, Walter.

Incentives for research, development, and innovation in pharmaceuticals

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Incentives for research, development, and innovation in pharmaceuticalsby Walter Garcia-Fontes (dir.).
其他作者:	Garcia-Fontes, Walter.
出版者:	Madrid :Springer Healthcare Iberica :2011.
面頁冊數:	ix, 96 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	DrugsResearch.
電子資源:	http://dx.doi.org/10.1007/978-84-938062-7-9
ISBN:	9788493806279 (electronic bk.)

Incentives for research, development, and innovation in pharmaceuticals
Incentives for research, development, and innovation in pharmaceuticals[electronic resource] /by Walter Garcia-Fontes (dir.). - Madrid :Springer Healthcare Iberica :2011. - ix, 96 p. :ill., digital ;24 cm. - Economia de la Salud y Gestion Sanitaria. - Economia de la Salud y Gestion Sanitaria..

Introduction -- Incentives for innovation: a survey -- Incentives for innovation: neglected diseases -- When patents are not enough: supplementary incentives for pharmaceutical innovation -- The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982 2003 -- The use of pay for performance for drugs: can it improve incentives for innovation? -- Drug Price Regulation: Recent Trends and Downstream Neglected Issues.

Incentives for innovation are particularly relevant in the pharmaceutical industry where not all social needs provide equally profitable opportunities and where most OECD countries try to implement diffe - rent measures that promote research in these less profitable areas. The lack of incentives for innovation is especially dramatic when we take into account diseases affecting mostly low-income countries, and also diseases affecting small groups of patients.How can incentives be provided to deal with these less profitable acti - vities when no clear markets exist for the innovations being introduced?Some of the contributions of this book go into discussing alternative mechanisms to substitute for these inexistent markets, and situations where traditional instruments such as public procurement or direct subsidies have proven totally insufficient. Also, this book discusses the clear mismatch between the size of the markets being targeted and the incentives being provided.

ISBN: 9788493806279 (electronic bk.)Subjects--Topical Terms:

184201
Drugs
--Research.

LC Class. No.: RM301.25 / .I53 2011

Dewey Class. No.: 615.19

Incentives for research, development, and innovation in pharmaceuticals
LDR:02330nmm a2200289 a 4500 001 353003
003 DE-He213
005 20121203131122.0
006 m d
007 cr nn 008maaau
008 121218s2011 sp s 0 eng d
020 $a 9788493806279 (electronic bk.)
020 $a 9788493806217 (paper)
035 $a 978-84-938062-7-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25 $b .I53 2011
082 0 4 $a 615.19 $2 23
090 $a RM301.25 $b .I36 2011
245 0 0 $a Incentives for research, development, and innovation in pharmaceuticals $h [electronic resource] / $c by Walter Garcia-Fontes (dir.).
260 $a Madrid : $b Springer Healthcare Iberica : $b Imprint: Springer Healthcare, $c 2011.
300 $a ix, 96 p. : $b ill., digital ; $c 24 cm.
490 1 $a Economia de la Salud y Gestion Sanitaria
505 0 $a Introduction -- Incentives for innovation: a survey -- Incentives for innovation: neglected diseases -- When patents are not enough: supplementary incentives for pharmaceutical innovation -- The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982 2003 -- The use of pay for performance for drugs: can it improve incentives for innovation? -- Drug Price Regulation: Recent Trends and Downstream Neglected Issues.
520 $a Incentives for innovation are particularly relevant in the pharmaceutical industry where not all social needs provide equally profitable opportunities and where most OECD countries try to implement diffe - rent measures that promote research in these less profitable areas. The lack of incentives for innovation is especially dramatic when we take into account diseases affecting mostly low-income countries, and also diseases affecting small groups of patients.How can incentives be provided to deal with these less profitable acti - vities when no clear markets exist for the innovations being introduced?Some of the contributions of this book go into discussing alternative mechanisms to substitute for these inexistent markets, and situations where traditional instruments such as public procurement or direct subsidies have proven totally insufficient. Also, this book discusses the clear mismatch between the size of the markets being targeted and the incentives being provided.
650 0 $a Drugs $x Research. $3 184201
650 0 $a Incentives in industry. $3 192137
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Health Promotion and Disease Prevention. $3 274213
650 2 4 $a Health Economics. $3 522380
650 2 4 $a Health Informatics. $3 274212
650 2 4 $a Medicine/Public Health, general. $3 273879
700 1 $a Garcia-Fontes, Walter. $3 584997
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Economia de la Salud y Gestion Sanitaria. $3 584998
856 4 0 $u http://dx.doi.org/10.1007/978-84-938062-7-9
950 $a Medicine (Springer-11650)